FDA Inspection 1012578 — Reese Pharmaceutical Company
The FDA completed an inspection of Reese Pharmaceutical Company on April 25, 2017 in Cleveland, OH. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 25, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Cleveland, OH (United States)